Quality of Friendships in Children With Neurofibromatosis
|ClinicalTrials.gov Identifier: NCT00508235|
Recruitment Status : Completed
First Posted : July 27, 2007
Last Update Posted : August 1, 2012
The aim of this study is to determine if children with a higher disease severity have lower quality friendships than children who are less severely affected and children who are unaffected. Researchers will test the hypothesis that the quality of friendships is inversely related to their disease severity.
- To use the FQQ to determine if the quality of friendships in children with NF1 is lower than the quality of friendships in unaffected children.
- To use a disease severity scale and the FQQ to determine if children who are less severely affected have higher friendship qualities than children who are more severely affected.
|Condition or disease||Intervention/treatment|
You (your) child will be asked to complete a short questionnaire (40 questions) about their relationship with their best friend. Doctors will review your (child's) medical chart to find out how severe the disease is, so that this may be compared to the answers you have (your child has) given on the friendship questionnaire.
This is an Investigational Study. About 90-100 children and adolescents with NF-1 will be asked to take part in this study. All will be enrolled at M.D. Anderson.
|Study Type :||Observational|
|Actual Enrollment :||61 participants|
|Official Title:||Quality of Friendships in Children With Neurofibromatosis: Relationship to Disease Severity|
|Study Start Date :||December 2004|
|Primary Completion Date :||July 2009|
|Study Completion Date :||July 2009|
Quality of Friendships
Patients with Neurofibromatosis, type 1 (NF-1) between the ages of 8 and 18 years old.
Questionnaire about the patient's relationship with their best friend.
Other Name: Survey
- Disease severity scale and Friendship Quality Questionnaire (FQQ) [ Time Frame: Questionnaire completion by patient and chart review by doctor for disease severity scoring. ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00508235
|United States, Texas|
|U.T.M.D. Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Bartlett D. Moore, PhD||M.D. Anderson Cancer Center|